Definition of Hypercoagulability, estrogen-associated
Hypercoagulability, estrogen-associated: Hypercoagulability (a supranormal tendency for blood to clot) occurs as an occasional but serious side effect of estrogen therapy.
The blood clots in this situation are dose-related, that is, they occur more frequently with higher doses of estrogen.
Estrogen therapy preparations (all of which carry this risk) include:
- esterified estrogens
- esterified estrogens and methyltestosterone
- estrogens (conjugated) and medroxyprogesterone
- estrogens conjugated
The brand names of the estrogen therapy preparations carrying this risk include:
- CLIMARA (estradiol)
- ESTRACE (estradiol)
- ESTRADERM (estradiol)
- ESTRATAB (esterified estrogens)
- ESTRATEST (esterified estrogens and methyltestosterone)
- MENEST (esterified estrogens)
- OGEN (estropipate)
- PREMARIN (estrogens conjugated)
- PREMPHASE (estrogens conjugated and medroxyprogesterone)
- PREMPRO (estrogens conjugated and medroxyprogesterone)
Cigarette smokers on estrogen therapy are at a higher risk than non-smokers for blood clots. Therefore, patients requiring estrogen therapy are strongly encouraged to quit smoking.Source: MedTerms™ Medical Dictionary
Last Editorial Review: 6/9/2016
Top RxList Drug News
Get tips on handling your hypertension.